[chuckles]

Well, Tyler, I'll, I'll see your shameless plug-in and I'll do you one better that's sooner.

Coming Monday, uh, we'll be talking about ADCs and, um, you know, sort of all things, uh, one-stop shop versus multi, and I think will be a big part of that, uh, event.

We have some really great, um, folks.

One of our editorial board members, um, is gonna be involved in it and, and some other, uh, um, consultants, um, you know, who are, who are well-versed in the industry, been there for, for a number of years.

Um, so, you know, again, tune into that as well, and I, I think it's, it's certainly stuff that, that is not going away, right? We could talk about this probably ad nauseam for, you know, many, many weeks, um, and still not scratch all the surface.

But, but you're right though, it is something that comes up a lot, like all of these different areas, um, whether it's ADCs or any other type of, you know, of multi-part drug.

Jeff?